Now with Motegrity, it's possible to take adult


Chronic Idiopathic Constipation (CIC) patients from

Stasis to peristalsis

Now with Motegrity, it's possible


to take adult Chronic Idiopathic


Constipation (CIC) patients from

Stasis to peristalsis

Enhanced colonic peristalsis is now possible with Motegrity,
the only FDA-approved selective serotonin type 4 (5-HT4) receptor
agonist for adults with CIC.1-4

Discover the Motegrity difference

Select Important Safety Information

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Motegrity is a GI prokinetic that enhances colonic peristalsis (i.e. HAPCs), which increases bowel motility

HAPCs=high amplitude propagating contractions

In a pharmacodynamic study in patients with CIC, a single 2 mg dose of Motegrity increased the number of HAPCs during the first 12 hours vs. an osmotic laxative treatment.1

Treatment with Motegrity 4 mg once daily (2X max recommended dose of 2 mg) for 7 days increased the amplitude of HAPCs in healthy subjects without affecting colonic phasic activity vs. placebo.1

See mechanism of action

HAPCs=high amplitude propagating contractions

Help your patients
save on Motegrity.

With the Motegrity savings card,
eligible patients can pay as little
as $15* per 30-day fill.

Find out more
Motegrity savings card

*Up to $90 max benefit per 30-day prescription. Terms and Conditions apply. See link above for details.

Clinical Efficacy

View the results established in 6 clinical trials in 2484 patients with CIC.1

See trial data
Bottle icon

Request Samples

Interested in receiving
samples of Motegrity?

Request Samples

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for persistent worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if their depression is persistently worse, or they experience emerging suicidal thoughts or behaviors.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

Indication

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

References:

1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Shire LLC. 2. Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Am J Gastroenterol. 2014;109(6):887-894. 3. Miner PB, Camilleri M, Burton D, et al. Neurogastroenterol Motil. 2016;28(9):1341-1348. 4. Enterostasis. Stedman's Online. https://stedmansonline.com/‌content.aspx‌?term=‌ENTEROSTASIS. Accessed February 25, 2019.